Skip to main content
Part of
Go to KD Group website

Top subsite menu

  • kdpharma
  • kdnutra
  • kdbiopharma
  • kdphyto

Service menu top

  • News
  • Clinicals
  • Careers
  • Contacts
Search

GLW Pharma menu

  • About us
  • Pipeline
  • Technology
  • Scientific publications

Submenu GLWPharma Pipeline

  • Introduction
  • Alfa®
  • What is FAP
  • Secondary Opportunity for KD Biopharma's Alfa®

Breadcrumb

  1. Home
  2. KD Biopharma
  3. Pipeline

Pipeline

KD Biopharma has different projects under assessment and is currently in the process of conducting Phase III of an orphan Drug named Alfa® indicated for the treatment of Familial Adenomatous Polyposis (FAP)

Alfa® has also shown to effectively help Ulcerative Colitis (UC) and Sporadic Polyps (SP) patients to keep the disease under control.

Product candidate (Pathway) Potencial indications Discovery Preclinical Phase 1 Phase 2 Phase 3
Alfa® FAP          
Alfa® UC          
Alfa® SP          
0

© 2017 KD Swiss GmbH, Bahnhofstrasse 21, 6300 Zug, Switzerland

TEL +41 417297183| info@kdpharmagroup.com

PRIVACY POLICY

Follow us

By By Your Interface SA